Indian Economy News

India Pharma 2026 concludes with a strong push for enhanced funding, infrastructure and speed to accelerate pharmaceutical innovation

The 9th edition of India Pharma 2026, organised by the Department of Pharmaceuticals in association with FICCI and the Indian Pharmaceutical Alliance (IPA), concluded after two days of extensive deliberations focused on strengthening India’s pharmaceutical and biopharma ecosystem. The second day featured two plenary sessions and a valedictory session, with discussions centred on building a stronger pharmaceutical financing ecosystem and shaping forward-looking pathways for innovation-led growth. Over 800 delegates, more than 60 national and international speakers, and 10 sessions supported by over 20 partner organisations underscored the scale of stakeholder engagement. The deliberations highlighted that strategic investments, infrastructure expansion and faster execution will be the three critical enablers for India’s next phase of pharmaceutical transformation.

A key theme emerging from the event was the sector’s shift from scale-led generics leadership to breakthrough innovation in advanced therapeutics, biologics and next-generation medicines. Discussions on financing stressed the importance of venture capital, private equity, blended finance and public-private partnerships to support long R&D cycles and high-risk innovation. Industry leaders, including Sun Pharmaceutical Industries, Zydus Lifesciences and Eli Lilly India, emphasised stronger collaboration between government, academia, investors and industry to build a resilient innovation ecosystem. The event reinforced India’s ambition to evolve into a global hub for advanced therapeutics and innovation-driven pharmaceutical growth, supported by deeper ecosystem linkages and AI-enabled transformation.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.